North America Anticoagulation Therapy Market, By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Testing Devices (In-Office Testing Devices, Analyzers, Reagents and Kits, Home Testing Devices), Services (Testing Services, Consulting), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2028.
Market Analysis and Insights : North America Anticoagulation Therapy Market
Anticoagulation therapy market size is projected to grow at a compound annual growth rate of 8% over the forecast period of 2021 to 2028. Data Bridge Market Research report on anticoagulation therapy market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the market’s growth.
Anticoagulation therapy is a type of medication which is used in prevention of blood clots formation and to endorse blood vessels open, they generally helps to prevent or to reduce blood clot formation/thrombi which further reduces their chances of developing serious conditions such as strokes and heart attacks.
The rapid rise in prevalence of arrhythmia, blood vessel thromboembolism and stroke and other cardiovascular diseases such as coronary artery disease across the globe are expected to accelerate the market growth in the forecast period of 2021 to 2028. Furthermore, increasing outpatient anticoagulation therapy, rising acceptance of NOAC’s, growing heparin trade and increasing awareness regarding anti-coagulants therapy among physicians further estimated to cushion the growth of the market. The use of anticoagulants as alternative to antiplatelet drugs, and increase in blood transfusions along with wide range of applications of anticoagulants further carve the way for the growth of the market. However, the high cost of developing drugs and lack of antidote for NOACs is projected to impede the market growth rate.
In addition, the growing research and development activities for the innovation of novel oral anticoagulants and growing number of pipeline products under clinical trials are likely to create various new opportunities that will impact this anticoagulation therapy market growth in the forecast period of 2021 to 2028. The high risk of malfunctions like increased bleeding are estimated to challenge the market’s growth.
This anticoagulation therapy market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the anticoagulation therapy market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
North America Anticoagulation Therapy Market Scope and Market Size
Anticoagulation therapy market is segmented on the basis of treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others.
- On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others.
- On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others.
- On the basis of testing devices, the market is segmented into in-office testing devices, analyzers, reagents and kits and home testing devices.
- On the basis of services, the market is segmented into testing services and consulting.
- On the basis of route of administration, the market is segmented into oral and injectable.
- On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
- On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement.
- On the basis of type, the market is segmented into generics and branded.
- On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others.
- On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Anticoagulation Therapy Market Country Level Analysis
Anticoagulation therapy market is analyzed and market size information is provided by treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel as referenced above.
The countries covered in the anticoagulation therapy market report are U.S., Canada and Mexico in North America.
U.S. dominates the anticoagulation therapy market due to the high prevalence of cardiovascular, increasing research and development activities and highly developed healthcare infrastructure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Anticoagulation therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and North America Anticoagulation Therapy Market Share Analysis
Anticoagulation therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to anticoagulation therapy market.
The major players covered in the anticoagulation therapy market report are Hikma Pharmaceuticals PLC, Mylan N.V., Teva Pharmaceutical Industries Ltd., Novartis AG, Eisai Co., Ltd., Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd, Fresenius Kabi AG, Aspen Holdings, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. , Cipla Inc, Johnson & Johnson Private Limited., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, DAIICHI SANKYO COMPANY, LIMITED, Eagle Pharmaceuticals, Inc., Endo International plc, Mitsubishi Tanabe Pharma Corporation, Taro Pharmaceutical Industries Ltd, among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-